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Total chemical synthesis of lassomycin and
lassomycin-amide†
S. Lear,a T. Munshi,b A. S. Hudson,a C. Hatton,a J. Clardy,c J. A. Mosely,a T. J. Bull,b
C. S. Sit*c and S. L. Cobb*a
Herein we report a practical synthetic route to the lasso peptide lassomycin (1) and C-terminal variant
lassomycin-amide (2). The biological evaluation of peptides 1 and 2 against Mycobacterium tuberculosis
revealed that neither had any activity against this bacterium. This lack of biological activity has led us to
propose that naturally occurring lassomycin may actually exhibit a standard lasso peptide threaded con-
formation rather than the previously reported unthreaded structure.
Introduction
The pressing issue of antimicrobial resistance continues to
drive the search for novel antibiotic scaﬀolds.1 Emerging
threats such as extensively drug-resistant tuberculosis require
the use of innovative approaches in the search for potential
leads.2,3 Lassomycin (1), a natural product belonging to the
‘lasso’ peptide class, was recently isolated from an Actino-
mycete (Lentzea kentuckyensis sp.) in a screen of a library of pre-
viously uncultured soil bacteria.4 The lasso peptide was found
to possess potent and specific bactericidal activity against
mycobacteria, including drug-resistant forms of Mycobacterium
tuberculosis. The specificity of activity arises due to the fact
that lassomycin targets the ClpC1 ATPase, an essential enzyme
in mycobacteria. ClpC1 ATPase is a key component of protein
degradation together with the ClpP1P2 proteolytic complex.5
The previously reported solution-state NMR structure of las-
somycin is shown in Fig. 1. The peptide does not adopt the
characteristic knot conformation reported for other homo-
logous lasso peptides: here the C-terminus packs tightly
against the N-terminal ring instead of passing through the
macrolactam.4 In light of this discovery, and the potential of
lasso peptides as novel drug scaﬀolds in general,6–8 we set out
to chemically synthesize the natural product.
Herein, we report the first chemical synthesis of the
recently identified lasso-peptide lassomycin (1) and a C-term-
inal amide derivative, lassomycin-amide (2). Synthetic peptides
1 and 2 were also evaluated for activity against M. tuberculosis.
Results and discussion
Two key structural features that need to be incorporated
during a chemical synthesis of lassomycin (1) are the iso-
peptide bond formed between the N-terminus and the carboxylate
side chain of Asp-8, and the methylated C-terminus (Fig. 1).
We envisaged two possible synthetic approaches to access las-
somycin (1) and these are outlined in Scheme 1. Route A
involved the preparation of a linear peptide and the formation
of the lactam ring on resin using an allyl ester orthogonal pro-
Fig. 1 Amino acid sequence and proposed solution-state NMR struc-
ture of lassomycin (1).4,9 The N- and C-terminus are labelled.
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tecting group strategy for the side chain of Asp-8. The C-term-
inal methyl ester would be installed using 2-chlorotrityl chlor-
ide resin and the approach reported by Turner et al.
(Scheme 1, Route A).10 The alternative approach (Scheme 1,
Route B), involved assembling the linear peptide on resin via
side chain anchoring. In this approach a di-peptide fragment
would be loaded initially onto the resin allowing the C-term-
inal methyl ester functionality to be installed at this point.
Lactam ring formation would be carried out in solution.
Initially, Route A (Scheme 1) was investigated and the linear
peptide 7 was successfully assembled via standard Fmoc solid
phase peptide synthesis (SPPS). Next, we attempted the on-
resin deprotection of the Asp-8 side chain. In our hands all
attempts to remove the allyl ester and generate peptide 6 were
unsuccessful, despite the use of stoichiometric amounts of tet-
rakis(triphenylphosphine)palladium(0) catalyst and triphenylsi-
lane, and trialling a number of reaction solvents. The lack of
success in allyl ester removal was assumed to arise from a
diﬃculty in coordinating the allyl moiety to the catalyst, presum-
ably due to steric hindrance around the metal centre. This eﬀect
will depend upon peptide sequence length and folding of the
peptide, and as such is likely to be highly sequence dependent.
In light of these diﬃculties alternative orthogonal protecting
groups were considered (i.e. highly acid sensitive,11 photolabile12
or silicon-based13 protection), however the requirement for more
specialized deprotection conditions, or the lack of available com-
mercial building blocks, led us to investigate Route B (Scheme 1).
The synthesis of the required orthogonally protected di-
peptide (10) for Route B was carried out in solution. Removal
of the t-butyl side chain from 10 under standard acidic con-
ditions followed by attachment to Rink amide resin gave the
methyl ester protected C-terminal fragment of lassomycin
(Scheme 2). The peptide chain was then extended on resin
using Fmoc SPPS to give a complete linear version of lasso-
mycin (4). Cleavage from the resin aﬀorded the linear peptide (3)
which was ready for lactam ring formation.
While peptide macrocyclizations are often best performed
under high dilution to minimize unwanted oligomer for-
mation,14 the ‘pseudo-high dilution’ conditions described by
Malesevic et al. were instead utilized as a more convenient
alternative in order to minimize solvent usage.15 11.3 mL
each of solutions of peptide 3 (0.01 M) and HATU (0.03 M)
in DMF were added to a reaction flask containing DIPEA
and HOAt over a period of ∼20 h at a rate of 0.01 mL min−1
(syringe pump controlled). Slow addition was used in order to
keep the eﬀective reaction concentration low, while requiring
only a relatively small final solvent volume (34 mL). Removal of
the solvent under vacuum and HPLC purification of the crude
reaction product yielded lassomycin (1) in high purity, as con-
firmed by analytical HPLC and MALDI-TOF MS (Fig. 2).
MALDI LIFT-TOF/TOF16 MS/MS was used to confirm the
correct sequence for the linear tail portion of lassomycin
(ESI†). However, fragmentation was not observed for the cyclic
region, but this matched the data reported by Gavrish et al.
from MS/MS sequencing of the isolated natural lassomycin.4 A
complete set of fragment ions were observed for the uncyclized
peptide.
Ion mobility (IM) mass spectrometry was also carried out
on the synthetic peptide. A number of peaks with distinct colli-
sional cross sections were resolved belonging to either lasso-
mycin or a trace amount of the C-terminal acid hydrolysis
product (13) (ESI Fig. 7†). Only a single peak was observed for
each species suggesting that only one conformation is present,
as opposed to distinct populations of threaded and
unthreaded peptide (or that the collisional cross section for
threaded/unthreaded ions is identical).
It was also possible to access lassomycin-amide (2) a
C-terminal amide version of the original lassomycin (1)
peptide. Synthesis of the required linear peptide (14) was
carried out on Rink amide resin using Fmoc SPPS, and clea-
vage from the resin aﬀorded peptide 15 (Scheme 3). Formation
of the lactam ring in solution and HPLC purification to yield
lassomycin-amide (2) were carried out as previously described
for the synthesis of 1. Purity and structure were confirmed by
analytical HPLC (ESI Fig. 2†), MALDI-TOF MS (ESI Fig. 2†) and
tandem mass spectrometry (ESI Fig. 1†).
Scheme 1 Proposed synthesis routes to lassomycin (1): (A) on resin cyclization and (B) combined solution/on-resin approach (amino acid side
chain protecting groups are omitted for clarity).
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Peptides 1 and 2, as well as truncated analogue lassomycin (1–9)
(16) representing the peptide without the tail were tested
against Mycobacterium tuberculosis H37Rv in MIC assays utili-
zing both solid-agar based and liquid-media based methods.
None of the peptides showed inhibitory activity when tested,
up to concentrations of 100 μg mL−1. These results were sur-
prising in particular for peptide 1, given the previously
reported biological activity profile.4 Given the unlikely nature
of spontaneous threading during the synthesis of 1 (and 2) it
is logical to assume that the peptides reported herein are un-
threaded. This, in combination with the biological data, leads
us to speculate that the un-threaded structure previously
reported may not be correct.
The structural discrepancy from the original report4
could possibly be due to instability of lassomycin in its
threaded conformation. Several examples have been docu-
mented of lasso peptides unthreading upon heat treatment.
Caulosegnin I unthreads completely after 4 hours at 95 °C,
while caulosegnin III unthreads and decomposes at elev-
ated temperatures.17 Similarly, astexin-1 unthreads when
heated to 50 °C for 4 hours18 and astexin-2 unthreads and
decomposes after heating at 95 °C for 2 hours.19 In con-
trast, caulosegnin II and astexin-3 show minimal to no
unthreading when heated at 95 °C for prolonged periods of
time.17,19
Scheme 2 Synthesis of lassomycin. The dipeptide Fmoc-Asp(OH)-Ile-OMe (12) was prepared in solution and anchored to Rink amide resin via the
Asp side chain. The required sequence was then elongated via SPPS, before global deprotection and cleavage from the resin. Cyclization of the
linear peptide in solution yielded the cyclic target. Reagents and conditions: (i) PyBOP® (1.0 equiv.) and NMM (3.0 equiv.), DCM, rt, 18 h; SiO2, 98/2%
hexane/EtOAc → 50/50% hexane/EtOAc, 63%; (ii) 40% TFA, DCM, rt, 30 min, 100%; (iii) Rink amide resin (0.79 mmol g−1), Fmoc-Asp(OH)-Ile-OMe
(12) (3.1 equiv.), PyBOP® (3.1 equiv.) and DIPEA (6.2 equiv.), DMF, RT, 2 × 1 h; (iv) Fmoc SPPS (see Experimental section); (v) TFA (95%, water), TIPS, rt,
4 h; (vi) HATU (3.0 equiv.) and DIPEA (6.0 equiv.), DMF, rt, 20 h (pseudo-high dilution, see text), 14%.
Fig. 2 HPLC trace (left) and MALDI-TOF mass spectrum (right) for syn-
thetic lassomycin (1). HPLC absorbance recorded at 220 nm, gradient
0–100% B over 30 min (A = 5 : 95 : 0.05 MeCN/H2O/TFA; B = 95 : 5 : 0.03
MeCN/H2O/TFA).
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In order to further elucidate the eﬀect of temperature on
the conformational state of lassomycin, structural characteriz-
ation of synthetic peptide 1 was carried out using two-dimen-
sional NMR. A comparison of 1H–13C HSQC spectra for 1 at
two diﬀerent temperatures is shown in Fig. 3. The NMR data
gathered is also compared in Fig. 3 with the naturally isolated
labelled [13C,15N]lassomycin.4 No noticeable changes in
chemical shift values are observed between the spectrum of 1
at 25 °C and at 40 °C. Furthermore, clear diﬀerences in the
1H–13C HSQC spectrum can be seen between the synthetic
peptide (1) and the naturally isolated lassomycin at 40 °C
(Fig. 3). These results strongly suggest that the conformation
of 1 does not change appreciably upon heating, and they high-
light that there are significant diﬀerences between the confor-
mation of synthetically prepared lassomycin (1) and that of
naturally isolated lassomycin.4
In light of this evidence, we propose that synthetic lasso-
mycin (1) either exists in the unconstrained unthreaded form,
or as a threaded lasso, but that there is no interconversion
between these structures at temperatures up to 40 °C. Given
the clear diﬀerences observed in the NMR between the syn-
thetic and naturally isolated lassomycin, it seems likely that
one peptide is threaded while the other is not. This idea of two
distinct conformations being adopted by the synthetic and
natural peptides is supported further by the biological data
obtained where clear diﬀerences in activity are seen.
We propose that (i) neither peptide has undergone
unthreading (or threading) upon heating during NMR data col-
lection, or (ii) one peptide has undergone threading from an
initial unthreaded state whilst the other has undergone
unthreading. For case (ii) the peptide undergoing unthreading
cannot be the naturally isolated lassomycin, as this would
imply that the synthetic peptide (1) has undergone threading
and that it is threaded at the point of NMR data collection,
thus paradoxically implying (given the NMR study of tempera-
ture dependence already discussed) that a threaded lassomycin
cannot unthread. Neither scenario therefore supports the
Scheme 3 Synthesis of lassomycin-amide (2). The peptide sequence
was synthesized via SPPS on Rink amide resin (0.79 mmol g−1), before
global deprotection and cleavage from the resin. Cyclization of the
linear peptide in solution yielded the cyclic target. Reagents and con-
ditions: (i) TFA (95%, water), TIPS, rt, 4 h; (ii) HATU (3.0 equiv.) and DIPEA
(6.0 equiv.), DMF, rt, 20 h (pseudo-high dilution, see text), 8%.
Fig. 3 Overlay of expanded regions of 1H–13C HSQC (heteronuclear single-quantum correlation) NMR spectra of naturally isolated [13C, 15N]lasso-
mycin at 40 °C (green), and synthetic lassomycin (1) at 25 °C (blue) and 40 °C (red). Clear diﬀerences in chemical shift values at 40 °C are observed
between 1 and the natural isolate. In contrast, shift values for the synthetic peptide (1) do not change noticeably over the temperature range sur-
veyed. (Full spectra given in the ESI.†)
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hypothesis that the naturally isolated lassomycin has under-
gone unthreading upon heating to 40 °C. Furthermore, given
the unlikely nature of scenario (ii), taken together with the pre-
viously discussed likelihood that synthetic lassomycin is in
fact unthreaded, we propose that the previously published
naturally isolated lassomycin actually exists as a threaded lasso
that does not unthread upon heating to 40 °C.
Conclusions
We have developed a practical synthetic route to an
unthreaded version of the lasso peptide lassomycin (1). Lasso-
mycin-amide (2), a C-terminal amide derivative of 1 was also
prepared. The biological evaluation of peptides 1 and 2 against
Mycobacterium tuberculosis revealed that neither had any
activity. A lack of biological activity and our NMR analysis of
synthetic lassomycin (1) suggest that naturally occurring lasso-
mycin exhibits a standard lasso peptide threaded confor-
mation rather than the reported unthreaded structure. Further
conformational studies to gain additional insight in this area
are ongoing.
Experimental
All reagents were purchased from Sigma-Aldrich unless other-
wise specified. Peptide synthesis grade DMF was purchased
from AGTC Bioproducts (Hessle, UK) and amino acid deriva-
tives were purchased from CEM, Novabiochem (Merck) or
AGTC. PyBOP® was purchased from Apollo Scientific (Stock-
port, UK). All resins were purchased from Novabiochem.
Peptide molecular weight calculations and mass assignments
were carried out using Pep-Calc.com.20
Peptide synthesis
Automated SPPS was carried out at 0.10 mmol scale on a CEM
Liberty1 single-channel microwave peptide synthesizer
equipped with a Discover microwave unit. All reactions were
carried out at room temperature in DMF using 2 × 1 h coup-
lings for all residues except Arg, which was triple coupled
(3 × 1 h). Fmoc-protected amino acids were used (5 equiv.), with
PyBOP® (5 equiv.) as the activator in the presence of DIPEA
(10 equiv., 2 M solution in NMP). Amino acid side chain func-
tionality was protected as follows: Fmoc-His(Trt)-OH, Fmoc-Ser
(OtBu)-OH and Fmoc-Thr(OtBu)-OH. The Fmoc group was
removed by two successive treatments with 20% (v/v) piper-
idine solution in DMF (5 + 10 min). An additional 10 min de-
protection was carried out for the penultimate residue (Leu-2).
Bubbling with nitrogen gas was used to ensure eﬃcient agita-
tion of the reaction mixture during each step. Preswelling of
dry resin was carried out in DMF for a minimum of 1 h.
Cleavage from solid support
Peptide-resin was shrunk in diethyl ether and treated with
2.85 mL TFA, 0.15 mL deionized water and 0.15 mL TIPS for
4 h at room temperature. The resin was then removed by fil-
tration and the filtrate concentrated in vacuo before precipi-
tation using ether and decanting of the liquid (followed by
subsequent ether washes). The resulting solid peptide was
dissolved in deionized water containing 0.1% TFA and
lyophilized.
Solution-phase cyclization
The cyclization was carried out using the pseudo-high
dilution conditions described by Malesevic et al.15 Fully
deprotected peptide (113 μmol) and HATU (339 μmol) were
dissolved separately in 11.3 mL each of DMF which had been
dried over molecular sieves. Both solutions were added simul-
taneously using two syringe pumps at a rate of 0.01 mL min−1
each to a stirred solution of HATU (11.3 μmol) and
DIPEA (678 μmol) in dry DMF (11.3 mL) over a period of
∼20 h. After the addition was complete, the reaction was
stirred for a further 30 min and the solvent was removed
under vaccum. The resulting oil was kept at −20 °C until
needed for purification.
High-performance liquid chromatography
The crude cyclization reaction product was dissolved in
2.5 mL deionized water/acetonitrile, filtered, centrifuged and
injected in 0.5 mL amounts (per run) onto a Speck and
Burke Analytical C18 Column (5.0 μm, 10.0 × 250 mm)
attached to a PerkinElmer Series 200 LC Pump and 785A
UV/Vis Detector. A linear gradient of 10–36% B (solvent A =
5 : 95 : 0.1 MeCN/H2O/TFA; B = 95 : 5 : 0.1 MeCN/H2O/TFA)
over 40 min, followed by 36–100% B over 20 min, with a
flow rate of 2 mL min−1 was used for separations. Absor-
bance data were collected at 220 nm. Selected fractions were
lyophilized and a mass assigned using MALDI-TOF MS or
ESI-MS, and peak fractions of interest were pooled and
lyophilized.
Nuclear magnetic resonance (NMR) spectroscopy
NMR spectra were collected using a Varian VNMRS 700 MHz.
Multiplicities: s = singlet, d = doublet, dd = doublet of doub-
lets, m = multiplet, t = triplet. Chemical shifts are reported in δ
units and are referenced to residual solvent peaks: CHCl3 (
1H
7.26 ppm, 13C 77.0 ppm) and DMSO (1H 2.50 ppm, 13C
39.5 ppm).
Analytical liquid chromatography mass spectrometry (LCMS)
Analytical LCMS was carried out using an Acquity UPLC
system (Waters Ltd, UK) equipped with a photodiode array
detector. Samples were injected onto an Acquity UPLC BEH
C18 column (1.7 μm, 2.1 × 50 mm) and a gradient of
5–95% B (solvent A = H2O, 0.1% formic acid; B = MeCN)
was run over 3.8 min with a flow rate of 0.6 mL min−1.
The flow of solvent from the UPLC system was introduced
into the electrospray ion source of an Aquity TQD or
QToF Premier mass spectrometer, and positive ions were
measured.
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Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS)
MALDI-TOF mass data was collected using an Autoflex II ToF/
ToF mass spectrometer (Bruker Daltonik GmBH) equipped
with a 337 nm nitrogen laser. Peptides were dissolved in 1 : 1
deionized water/MeCN for MS analysis. Sample solution
(1 mg mL−1) was mixed with matrix solution (α-cyano-
4-hydroxycinnamic acid, ∼50 mg mL−1) in a ratio of 1 : 9, and
1 μL of the resulting solution spotted onto a metal target and
placed into the MALDI ion source. MS data was processed using
FlexAnalysis 2.0 (Bruker Daltonik GmBH). MALDI MS/MS was
performed using LIFT technology, which enables detection of
product ions that result from elevating the laser power.
Ion-mobility (IM) mass spectrometry
Ion-mobility mass spectrometry was carried out using a Synapt
G2S mass spectrometer equipped with an Acquity UPLC
(Waters Ltd, UK). 1 μL of sample was injected onto a BEH C18
column (1.7 μm, 2.1 × 100 mm) and a gradient of 5–95% B
(solvent A = H2O, 0.1% formic acid; B = MeCN, 0.1% formic
acid) was run over 6.0 min with a flow rate of 0.4 mL min−1. A
photodiode array detector provided absorbance data from
200 nm to 500 nm. The solvent flow was introduced into the
electrospray ion source, and full scan MS carried out for posi-
tive ions. IM separation was performed with nitrogen as the
gas. MS and photodiode array absorbance data was processed
using MassLynx 4.1 (Waters Ltd, UK). IM results are rep-
resented as a plot of m/z against drift time in Bins
(mobiliogram).
MIC testing of compounds against mycobacteria
The MICs of the compounds were determined using standard
liquid-broth and solid-agar based methods. Briefly, serial
dilutions of each compound were made between 100 mg L−1
and 0.78 mg L−1 with MB7H9/OADC (BD Biosciences) media
in 96-well U-bottom plates. Mycobacterium tuberculosis H37Rv
was grown to log phase (OD600 = 1.0) and 10
4 cells were added
to all wells. Solid-agar based method was carried out as pre-
viously described21 using a 48-well plate format. Compounds
(see above) were tested in triplicate by adding serial dilutions
into separate wells overlaid with MB7H11/OADC (BD Bio-
sciences) agar based media. Mycobacterium tuberculosis culture
(5 µL containing 104 cells) was then inoculated into the centre
of each well on top of the solidified media. Plates were sealed
and incubated at 37 °C in 5% CO2 for 10 days. Each plate also
contained standardised serial dilution controls of first line TB
drugs isoniazid (INH [Sigma, UK]; concentration range 8, 4, 2,
1, 0.5, 0.25, 0.125, 0.0625 µg mL−1) and rifampicin (RIF
[Sigma, UK]; concentration range 16, 8, 4, 2, 1, 0.5, 0.25,
0.125 µg mL−1), in addition to negative (media only) controls.
The MICs were determined as the first dilution to show com-
plete growth inhibition as determined by a total lack of colony
formation within the test period. It was not possible to obtain
an authentic sample of naturally isolated lassomycin to
compare in this assay because the Lentzea kentuckyensis sub-
species from which lassomycin was originally prepared is the
property of NovoBiotic Pharmaceuticals and was unavailable.
Compounds
Fmoc-Asp(OtBu)-Ile-OMe (10). Fmoc-Asp-(OtBu)-OH (1.14 g,
1.0 equiv., 2.77 mmol), H-Ile-OMe (0.40 g, 1.0 equiv.,
2.77 mmol) and PyBOP® (1.44 g, 1.0 equiv., 2.77 mmol) were
suspended in DCM (30 mL) and stirred at room temperature.
N-Methylmorpholine (0.91 mL, 3.0 equiv., 8.31 mmol) was
added and the reaction was stirred at room temperature for
18 h. The crude reaction mixture was evaporated under
reduced pressure and purified via column chromatography
(SiO2; 98/2% hexane/EtOAc → 50/50% hexane/EtOAc) to yield
Fmoc-Asp(OtBu)-Ile-OMe (10) as a white powder (0.93 g,
63%), δH (700 MHz, CDCl3) 0.88–0.93 (3H, m, Ile-δCH3),
0.88–0.93 (3H, m, Ile-γCH3), 1.15–1.23 (1H, m, Ile-γCH2),
1.38–1.44 (1H, m, Ile-γCH2), 1.46 (9H, s, OtBu), 1.89–1.95 (1H,
m, Ile-βCH), 2.64 (1H, dd, J 17.3 and 7.3 Hz, Asp-βCH2), 2.93
(1H, dd, J 17.3 and 4.1 Hz, Asp-βCH2), 3.71 (3H, s, CO2CH3),
4.23 (1H, t, J 7.1 Hz, FmocCH), 4.41 (2H, d, J 7.1 Hz,
FmocCH2), 4.53 (1H, dd, J 8.6 and 4.8 Hz, Ile-αCH), 4.58–4.63
(1H, m, Asp-αCH), 6.08 (1H, d, J 8.2 Hz, AspNH), 7.16 (1H, d,
J 8.6 Hz, IleNH), 7.31 (2H, t, J 7.5 Hz, FmocArH), 7.40 (2H, t,
J 7.5 Hz, FmocArH), 7.59 (2H, d, J 7.5 Hz, FmocArH), 7.76 (2H,
d, J 7.5 Hz, FmocArH); δC (176 MHz, CDCl3) 11.6, 15.6, 25.1,
28.1, 37.6, 47.2, 50.9, 52.1, 56.9, 67.4, 82.0, 120.1, 125.1, 127.2,
127.8, 141.4, 143.7, 143.9, 156.0, 170.6, 171.6, 171.9; HRMS
m/z (ESI) 539.2756, consistent with empirical formula
C30H39N2O7 with an accuracy of 0.2 ppm (accepted as
[M + H]+).
Fmoc-Asp(OH)-Ile-OMe (12). Fmoc-Asp(OtBu)-Ile-OMe (10,
0.33 g, 0.61 mmol) was treated with 20 mL of TFA solution
(40% in DCM) for 30 min. Complete removal of the t-butyl
group was confirmed using TLC. The reaction mixture was
evaporated under reduced pressure to give Fmoc-Asp(OH)-Ile-
OMe (12) as a white powder (quantitative yield, 0.29 g) which
was used without further purification. δH (700 MHz, CDCl3)
0.86–0.91 (3H, m, Ile-δCH3), 0.86–0.91 (3H, m, Ile-γCH3),
1.11–1.20 (1H, m, Ile-γCH2), 1.35–1.44 (1H, m, Ile-γCH2),
1.85–1.96 (1H, m, Ile-βCH), 2.78 (1H, dd, J 17.4 and 6.4 Hz,
Asp-βCH2), 3.03 (1H, d, J 17.4 Hz, Asp-βCH2), 3.72 (3H, s,
CO2CH3), 4.22 (1H, t, J 6.6 Hz, FmocCH), 4.43 (2H, d, J 6.6 Hz,
FmocCH2), 4.53 (1H, dd, J 8.4 and 4.7 Hz, Ile-αCH), 4.60–4.69
(1H, m, Asp-αCH), 5.97 (1H, d, J 8.0 Hz, AspNH), 7.09 (1H, d,
J 8.4 Hz, IleNH), 7.31 (2H, t, J 7.5 Hz, FmocArH), 7.40 (2H, t,
J 7.5 Hz, FmocArH), 7.57 (2H, d, J 7.5 Hz, FmocArH), 7.76 (2H,
d, J 7.5 Hz, FmocArH); HRMS m/z (ESI) 483.2115, consistent
with empirical formula C26H31N2O7 with an accuracy of
3.3 ppm (accepted as [M + H]+).
Lassomycin (1). The dipeptide Fmoc-Asp(OH)-Ile-OMe (12)
was coupled manually to Rink amide AM resin (0.79 mmol per
g substitution, 0.10 mmol scale) using two 1 h couplings at rt.
The sequence GLRRLFADQLVGRR was then built onto the
resin-supported dipeptide via automated SPPS at room temp-
erature (as described). Resin cleavage, cyclization and purifi-
cation by high-performance liquid chromatography were
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carried out as detailed above to aﬀord lassomycin (26 mg,
14%), MALDI-TOF mass: found m/z 1881.1 [M + H]+, calcd
1881.2 [M + H]+; HRMS m/z (ESI) 940.55785, consistent with
empirical formula C83H144N30O20 with an accuracy of 0.3 ppm
(accepted as [M + 2H]2+).
Lassomycin-amide (2). Linear peptide GLRRLFADQLVGRRNI-
amide was synthesized via automated SPPS at room tempera-
ture (as described) on Rink amide AM resin (0.79 mmol per g
substitution, 0.10 mmol scale). Resin cleavage, cyclization and
purification by high-performance liquid chromatography were
carried out as detailed above to aﬀord lassomycin-amide
(4 mg, 8%), MALDI-TOF mass: found m/z 1866.2 [M + H]+,
calcd 1866.2 [M + H]+; HRMS m/z (ESI) 933.06000, consistent
with empirical formula C82H143N31O19 with an accuracy of
1.8 ppm (accepted as [M + 2H]2+).
Lassomycin(1–9) (17). Linear peptide GLRRLFADQ-amide
was synthesized via automated SPPS on Rink amide AM resin
(0.79 mmol per g substitution, 0.10 mmol scale). Resin clea-
vage, cyclization and purification by high-performance liquid
chromatography aﬀorded lassomycin(1–9) (31 mg, 29%),
MALDI-TOF mass: found m/z 1056.6 [M + H]+, calcd 1057.2
[M + H]+; HRMS m/z (ESI) 1056.6082, consistent with empirical
formula C47H78N17O11 with an accuracy of 1.4 ppm (accepted
as [M + H]+).
Abbreviations
AM Aminomethyl
ATP Adenosine triphosphate
DCM Dichloromethane
DIPEA N,N-Diisopropylethylamine
DMF N,N-Dimethylformamide
DMSO Dimethyl sulfoxide
ES Electrospray
ESI Electrospray ionization
Fmoc Fluorenylmethyloxycarbonyl
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo-
[4,5-b]pyridinium 3-oxid hexafluorophosphate
HOAt 3H-[1,2,3]-Triazolo[4,5-b]pyridin-3-ol
HPLC High-performance liquid chromatography
IM Ion-mobility
LC Liquid chromatography
LIFT LIFT
MALDI Matrix-assisted laser desorption/ionization
MeCN Acetonitrile
MIC Minimum inhibitory concentration
MS Mass spectrometry
NMM N-Methylmorpholine
NMR Nuclear magnetic resonance
Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl
PyBOP® (Benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate
rt Room temperature
SPPS Solid-phase peptide synthesis
tBu tert-Butyl
TFA Trifluoroacetic acid
TIPS Triisopropylsilane
TLC Thin-layer chromatography
TOF Time of flight
Trt Triphenylmethyl
UPLC Ultra-performance liquid chromatography
UV Ultraviolet
HRMS High-resolution mass spectrometry
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